Drug intelligence / Profile preview

exosomes + ecklonia cava extract + thuja orientalis extract

Development stage
Unknown
Lead developer
Cosmedician AP
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intradermal
01

Overview

This is a combination formulation consisting of **exosomes**, **Ecklonia cava extract**, and **Thuja orientalis extract**. The drug is under investigation primarily for the treatment of **androgenetic alopecia** (male pattern hair loss). - **Exosomes** are small extracellular vesicles derived from cells that serve as carriers of molecular signals and growth factors. In the context of alopecia treatment, exosomes act as cell-free agents to promote hair follicle regeneration and recalibrate the hair growth cycle, stimulating hair follicles to transition from dormant to active growth phases[1][3][5]. - **Ecklonia cava extract** is derived from a marine brown alga and is rich in bioactive compounds, notably **phlorotannins** and **fucoidans**, with antioxidant and anti-inflammatory properties. It reduces oxidative stress in dermal papilla cells, inhibits androgen-induced TGF-β1, and suppresses **5α-reductase** activity, lowering dihydrotestosterone (DHT) levels—a key driver in hair loss[1]. - **Thuja orientalis extract** is derived from the leaves of the medicinal plant T. orientalis. It has been shown to promote the proliferation and regeneration of hair follicles by activating the **β-catenin** and **Sonic hedgehog (Shh)** signaling pathways, encouraging transition into the anagen (growth) phase[1][6]. The combination has been evaluated in a randomized controlled clinical trial that demonstrated significant efficacy for hair regrowth and improvement in hair density in males with Norwood grades 2–3 androgenetic alopecia when compared to placebo[1][5]. The product is still investigational and not yet approved for marketing.

Other names
ECPE
02

Targets

SRD5A (Steroid 5-alpha-reductase)TGFB1 (Transforming growth factor Beta-1 proprotein)CTNNB1 (Beta-catenin)SHH (Sonic hedgehog)

Beyond the preview

Go deeper on exosomes + ecklonia cava extract + thuja orientalis extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on exosomes + ecklonia cava extract + thuja orientalis extract.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call